Stockscreener 앱 받기
4.90
2.78%
-0.14
시간 외 거래:
4.99
0.09
+1.84%
전일 마감가:
$5.04
열려 있는:
$5.03
하루 거래량:
557.69K
Relative Volume:
0.88
시가총액:
$246.82M
수익:
$230.47M
순이익/손실:
$30.28M
주가수익비율:
8.0328
EPS:
0.61
순현금흐름:
$38.86M
1주 성능:
-6.67%
1개월 성능:
-4.48%
6개월 성능:
+52.65%
1년 성능:
+66.10%
1일 변동 폭
$4.86
$5.10
1주일 범위
$4.86
$5.515
52주 변동 폭
$2.32
$6.07
Puma Biotechnology Inc Stock (PBYI) Company Profile
명칭
Puma Biotechnology Inc
전화
(424) 248-6500
주소
10880 WILSHIRE BLVD., LOS ANGELES, CA
PBYI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
4.90 | 253.87M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Underperform |
| 2019-10-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-10 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-01-17 | 개시 | Leerink Partners | Mkt Perform |
| 2019-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-11-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-11-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-17 | 개시 | Goldman | Sell |
| 2018-05-11 | 재확인 | Stifel | Buy |
| 2017-11-10 | 재확인 | Citigroup | Buy |
| 2017-11-10 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | 재확인 | Stifel | Buy |
| 2017-09-11 | 재확인 | Credit Suisse | Outperform |
| 2017-07-10 | 재개 | Leerink Partners | Outperform |
| 2017-06-06 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | 재확인 | RBC Capital Mkts | Sector Perform |
모두보기
Puma Biotechnology Inc 주식(PBYI)의 최신 뉴스
Using fundamentals and technicals on Puma Biotechnology Inc.2025 Growth vs Value & Fast Gain Stock Trading Tips - newser.com
Using data filters to optimize entry into Puma Biotechnology Inc.Quarterly Portfolio Report & Verified Momentum Stock Watchlist - newser.com
Using R and stats models for Puma Biotechnology Inc. forecastingQuarterly Risk Review & Safe Capital Growth Stock Tips - newser.com
How strong is Puma Biotechnology Inc. stock revenue growthMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Using Ichimoku Cloud for Puma Biotechnology Inc. technicalsPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
How institutional buying supports Puma Biotechnology Inc. stockMarket Activity Report & Daily Oversold Bounce Ideas - newser.com
Is Puma Biotechnology Inc. reversing from oversold territoryJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Can Puma Biotechnology Inc. stock withstand economic slowdown2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Global Desmoid Tumors Market Report 2025: Regional and Country-Level Analysis & Forecast to 2035 Featuring SpringWorks Therapeutics, Ayala Pharma, Puma Biotechnology, BMS, Eli Lilly, Ipsen, Deciphera Pharma - Yahoo Finance
Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Will Puma Biotechnology Inc. stock remain a Wall Street favorite - fcp.pa.gov.br
Why retail investors favor Puma Biotechnology Inc. stockInflation Watch & Safe Entry Momentum Tips - fcp.pa.gov.br
Puma Biotechnology Stock Up 11%, Buy Or Wait? - Trefis
Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold (C+) Rating by Weiss Ratings - MarketBeat
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2025 Financial Results - BioSpace
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - The AI Journal
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN
Puma Biotechnology Inc (PBYI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):